Skip to main content
SpringerLink
Log in

Treatment of Stiff-Person Spectrum Disorders

  • Chapter
  • First Online:
Stiff-Person Syndrome and Related Disorders

  • 528 Accesses

Abstract

Treatment of stiff-person spectrum disorders is usually divided into symptomatic and specific therapies. Symptomatic therapies include benzodiazepines, baclofen, tizanidine, and, less commonly, antiepileptic medications. The most commonly used medication for symptomatic treatment is diazepam. Given autoimmunity as a main pathophysiological basis, specific immunotherapies therapies include corticosteroids, corticosteroid-sparing agents, intravenous immunoglobulin, plasma exchange, and rituximab. Data from clinical trials to suggest treatment selection in clinical practice remain lacking, given the rarity of SPSD. Multiple different approaches are based on clinical experience. The targeted approach with stratification of patients by severity and clinical phenotypes is recommended. In patients with severe symptoms or aggressive phenotypes such as progressive encephalomyelitis with rigidity and myoclonus, immunotherapies should be considered early.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Howard FM Jr. A new and effective drug in the treatment of the stiff-man syndrome: preliminary report. Proc Staff Meet Mayo Clin. 1963;38:203–12.

    PubMed  Google Scholar 

  2. Siegel GJ, Agranoff BW. Basic neurochemistry: molecular, cellular, and medical aspects. 6th ed ed. Philadelphia: Lippincott-Raven Publishers; 1999.

    Google Scholar 

  3. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11(Suppl 1):11S–6S. https://doi.org/10.1111/j.1365-2125.1981.tb01833.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214–23.

    PubMed  PubMed Central  Google Scholar 

  5. McIntosh B, Clark M, Spry C. Benzodiazepines in older adults: a review of clinical effectiveness, cost-effectiveness, and guidelines. CADTH Rapid Response Reports. Ottawa; 2011.

    Google Scholar 

  6. Westblom U. Stiff-man syndrome and clonazepam. JAMA. 1977;237(18):1930.

    Article  CAS  PubMed  Google Scholar 

  7. Vasconcelos OM, Dalakas MC. Stiff-person Syndrome. Curr Treat Options Neurol. 2003;5(1):79–90. https://doi.org/10.1007/s11940-003-0024-x.

    Article  PubMed  Google Scholar 

  8. Gordon EE, Januszko DM, Kaufman L. A critical survey of stiff-man syndrome. Am J Med. 1967;42(4):582–99. https://doi.org/10.1016/0002-9343(67)90057-5.

    Article  CAS  PubMed  Google Scholar 

  9. Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc. 1989;64(6):629–36. https://doi.org/10.1016/s0025-6196(12)65339-7.

    Article  CAS  PubMed  Google Scholar 

  10. Folli F, Prioletta A, Quattrini A, Galardi G. Stiff-man syndrome. In: Katirji B, Kaminski HJ, Ruff RL, editors. Neuromuscular disorders in clinical practice. Second ed. New York: Sprinker; 2014. p. 1465–77.

    Chapter  Google Scholar 

  11. Whelan JL. Baclofen in treatment of the ‘stiff-man’ syndrome. Arch Neurol. 1980;37(9):600–1. https://doi.org/10.1001/archneur.1980.00500580096024.

    Article  CAS  PubMed  Google Scholar 

  12. Miller F, Korsvik H. Baclofen in the treatment of stiff-man syndrome. Ann Neurol. 1981;9(5):511–2. https://doi.org/10.1002/ana.410090516.

    Article  CAS  PubMed  Google Scholar 

  13. Penn RD, Mangieri EA. Stiff-man syndrome treated with intrathecal baclofen. Neurology. 1993;43(11):2412. https://doi.org/10.1212/wnl.43.11.2412.

    Article  CAS  PubMed  Google Scholar 

  14. Seitz RJ, Blank B, Kiwit JC, Benecke R. Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. J Neurol. 1995;242(10):618–22. https://doi.org/10.1007/bf00866910.

    Article  CAS  PubMed  Google Scholar 

  15. Silbert PL, Matsumoto JY, McManis PG, Stolp-Smith KA, Elliott BA, McEvoy KM. Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology. 1995;45(10):1893–7. https://doi.org/10.1212/wnl.45.10.1893.

    Article  CAS  PubMed  Google Scholar 

  16. Stayer C, Tronnier V, Dressnandt J, Mauch E, Marquardt G, Rieke K, et al. Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. Neurology. 1997;49(6):1591–7. https://doi.org/10.1212/wnl.49.6.1591.

    Article  CAS  PubMed  Google Scholar 

  17. Meinck HM, Tronnier V, Rieke K, Wirtz CR, Flugel D, Schwab S. Intrathecal baclofen treatment for stiff-man syndrome: pump failure may be fatal. Neurology. 1994;44(11):2209–10. https://doi.org/10.1212/wnl.44.11.2209.

    Article  CAS  PubMed  Google Scholar 

  18. Bardutzky J, Tronnier V, Schwab S, Meinck HM. Intrathecal baclofen for stiff-person syndrome: life-threatening intermittent catheter leakage. Neurology. 2003;60(12):1976–8. https://doi.org/10.1212/wnl.60.12.1976.

    Article  CAS  PubMed  Google Scholar 

  19. Ghanavatian S, Derian A. Tizanidine. Treasure Island: StatPearls; 2019.

    Google Scholar 

  20. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand. 1994;89(4):274–9. https://doi.org/10.1111/j.1600-0404.1994.tb01680.x.

    Article  CAS  PubMed  Google Scholar 

  21. Meinck HM, Ricker K, Conrad B. The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry. 1984;47(3):280–7. https://doi.org/10.1136/jnnp.47.3.280.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zdziarski P. A case of stiff person syndrome: immunomodulatory effect of benzodiazepines: successful rituximab and tizanidine therapy. Medicine (Baltimore). 2015;94(23):e954. https://doi.org/10.1097/MD.0000000000000954.

    Article  CAS  Google Scholar 

  23. Spehlmann R, Norcross K, Rasmus SC, Schlageter NL. Improvement of stiff-man syndrome with sodium valproate. Neurology. 1981;31(9):1162–3. https://doi.org/10.1212/wnl.31.9.1162.

    Article  CAS  PubMed  Google Scholar 

  24. Vermeij FH, van Doorn PA, Busch HF. Improvement of stiff-man syndrome with vigabatrin. Lancet. 1996;348(9027):612. https://doi.org/10.1016/S0140-6736(05)64825-8.

    Article  CAS  PubMed  Google Scholar 

  25. Prevett MC, Brown P, Duncan JS. Improvement of stiff-man syndrome with vigabatrin. Neurology. 1997;48(4):1133–4. https://doi.org/10.1212/wnl.48.4.1133-a.

    Article  CAS  PubMed  Google Scholar 

  26. Murinson BB, Rizzo M. Improvement of stiff-person syndrome with tiagabine. Neurology. 2001;57(2):366. https://doi.org/10.1212/wnl.57.2.366.

    Article  CAS  PubMed  Google Scholar 

  27. Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004;62(2):338. https://doi.org/10.1212/01.wnl.0000103442.27580.5b.

    Article  PubMed  Google Scholar 

  28. Sechi G, Barrocu M, Piluzza MG, Cocco GA, Deiana GA, Sau GF. Levetiracetam in stiff-person syndrome. J Neurol. 2008;255(11):1721–5. https://doi.org/10.1007/s00415-008-0007-7.

    Article  PubMed  Google Scholar 

  29. Voci JM, al-Hakim M, Dokko Y, Katirji MB. Intravenous methocarbamol in the treatment of stiff-man syndrome. Muscle Nerve. 1993;16(4):434–5.

    CAS  PubMed  Google Scholar 

  30. Davis D, Jabbari B. Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A. Mov Disord. 1993;8(3):371–3. https://doi.org/10.1002/mds.870080323.

    Article  CAS  PubMed  Google Scholar 

  31. Liguori R, Cordivari C, Lugaresi E, Montagna P. Botulinum toxin A improves muscle spasms and rigidity in stiff-person syndrome. Mov Disord. 1997;12(6):1060–3. https://doi.org/10.1002/mds.870120636.

    Article  CAS  PubMed  Google Scholar 

  32. Conners LM, Betcher A, Shahinian A, Janda P. Utility of botulinum injections in stiff-person syndrome. Case Rep Neurol Med. 2019;2019:9317916. https://doi.org/10.1155/2019/9317916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Barnes PJ. How corticosteroids control inflammation: quintiles prize lecture 2005. Br J Pharmacol. 2006;148(3):245–54. https://doi.org/10.1038/sj.bjp.0706736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin N Am. 2016;42(1):15–31., vii. https://doi.org/10.1016/j.rdc.2015.08.002.

    Article  Google Scholar 

  35. Piccolo G, Cosi V, Zandrini C, Moglia A. Steroid-responsive and dependent stiff-man syndrome: a clinical and electrophysiological study of two cases. Ital J Neurol Sci. 1988;9(6):559–66. https://doi.org/10.1007/bf02337009.

    Article  CAS  PubMed  Google Scholar 

  36. Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018;80:331–6. https://doi.org/10.1016/j.yebeh.2018.01.021.

    Article  PubMed  Google Scholar 

  37. Hartung HP. Advances in the understanding of the mechanism of action of IVIG. J Neurol. 2008;255(Suppl 3):3–6. https://doi.org/10.1007/s00415-008-3002-0.

    Article  CAS  PubMed  Google Scholar 

  38. Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous immunoglobulin. Front Immunol. 2018;9:1189. https://doi.org/10.3389/fimmu.2018.01189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29(11):491–8. https://doi.org/10.1093/intimm/dxx039.

    Article  CAS  PubMed  Google Scholar 

  40. Amato AA, Cornman EW, Kissel JT. Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology. 1994;44(9):1652–4. https://doi.org/10.1212/wnl.44.9.1652.

    Article  CAS  PubMed  Google Scholar 

  41. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345(26):1870–6. https://doi.org/10.1056/NEJMoa01167.

    Article  CAS  PubMed  Google Scholar 

  42. Stern WM, Howard R, Chalmers RM, Woodhall MR, Waters P, Vincent A, et al. Glycine receptor antibody mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome. Pract Neurol. 2014;14(2):123–7. https://doi.org/10.1136/practneurol-2013-000511.

    Article  CAS  PubMed  Google Scholar 

  43. Molina JA, Porta J, Garcia-Morales I, Bermejo PF, Jimenez-Jimenez FJ. Treatment with intravenous prednisone and immunoglobin in a case of progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 2000;68(3):395–6. https://doi.org/10.1136/jnnp.68.3.395a.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Uehara T, Murai H, Yamasaki R, Kikuchi H, Shigeto H, Ohyagi Y, et al. Thymoma-associated progressive encephalomyelitis with rigidity and myoclonus successfully treated with thymectomy and intravenous immunoglobulin. Eur Neurol. 2011;66(6):328–30. https://doi.org/10.1159/000332033.

    Article  PubMed  Google Scholar 

  45. Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839–87. https://doi.org/10.1152/physrev.00010.2016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Quek AM, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69(5):582–93. https://doi.org/10.1001/archneurol.2011.2985.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lauria G, Pareyson D, Pitzolu MG, Bazzigaluppi E. Excellent response to steroid treatment in anti-GAD cerebellar ataxia. Lancet Neurol. 2003;2(10):634–5. https://doi.org/10.1016/s1474-4422(03)00534-9.

    Article  PubMed  Google Scholar 

  48. Bonnan M, Cabre P, Olindo S, Signate A, Saint-Vil M, Smadja D. Steroid treatment in four cases of anti-GAD cerebellar ataxia. Rev Neurol (Paris). 2008;164(5):427–33. https://doi.org/10.1016/j.neurol.2008.02.032.

    Article  CAS  Google Scholar 

  49. Vicari AM, Folli F, Pozza G, Comi GC, Comola M, Canal N, et al. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med. 1989;320(22):1499.

    CAS  PubMed  Google Scholar 

  50. Brashear HR, Phillips LH 2nd. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology. 1991;41(10):1588–92. https://doi.org/10.1212/wnl.41.10.1588.

    Article  CAS  PubMed  Google Scholar 

  51. Fogan L. Progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosuppression. Ann Neurol. 1996;40(3):451–3. https://doi.org/10.1002/ana.410400315.

    Article  CAS  PubMed  Google Scholar 

  52. Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006;63(7):930–5. https://doi.org/10.1001/archneur.63.7.930.

    Article  PubMed  Google Scholar 

  53. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anti-Cancer Drugs. 2002;13(Suppl 2):S3–10. https://doi.org/10.1097/00001813-200211002-00002.

    Article  CAS  PubMed  Google Scholar 

  54. Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39(4):131–4. https://doi.org/10.18773/austprescr.2016.053.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Lobo ME, Araujo ML, Tomaz CA, Allam N. Stiff-person syndrome treated with rituximab. BMJ Case Rep. 2010;2010 https://doi.org/10.1136/bcr.05.2010.3021.

    Google Scholar 

  56. Dupond JL, Essalmi L, Gil H, Meaux-Ruault N, Hafsaoui C. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci. 2010;17(3):389–91. https://doi.org/10.1016/j.jocn.2009.06.015.

    Article  CAS  PubMed  Google Scholar 

  57. Katoh N, Matsuda M, Ishii W, Morita H, Ikeda S. Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med. 2010;49(3):237–41. https://doi.org/10.2169/internalmedicine.49.2821.

    Article  CAS  PubMed  Google Scholar 

  58. Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc. 2010;60(1):64–5.

    PubMed  Google Scholar 

  59. Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82(2):271–7. https://doi.org/10.1002/ana.25002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Sengupta S, Tarsy D, Joyce R, Jeyapalan S. Novel use of dual immunomodulation for treating stiff-person syndrome, cerebellar variant. Mov Disord. 2013;28(13):1905–6. https://doi.org/10.1002/mds.25574.

    Article  PubMed  Google Scholar 

  61. Triplett J, Vijayan S, MacDonald A, Lawn N, McLean-Tooke A, Bynevelt M, et al. Fulminant anti-GAD antibody encephalitis presenting with status epilepticus requiring aggressive immunosuppression. J Neuroimmunol. 2018;323:119–24. https://doi.org/10.1016/j.jneuroim.2018.06.013.

    Article  CAS  PubMed  Google Scholar 

  62. Termsarasab P, Katirji B. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil. J Neuroimmunol. 2012;249(1–2):83–5. https://doi.org/10.1016/j.jneuroim.2012.04.016.

    Article  CAS  PubMed  Google Scholar 

  63. Termsarasab P, Katirji B. Brainstem lymphoma in a myasthenia gravis patient on azathioprine. J Clin Neurosci. 2015;22(2):415–8. https://doi.org/10.1016/j.jocn.2014.06.104.

    Article  PubMed  Google Scholar 

  64. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–4. https://doi.org/10.1172/JCI18384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118. https://doi.org/10.1016/s0162-3109(00)00188-0.

    Article  CAS  PubMed  Google Scholar 

  66. Sevy A, Franques J, Chiche L, Pouget J, Attarian S. Successful treatment with rituximab in a refractory stiff-person syndrome. Rev Neurol (Paris). 2012;168(4):375–8. https://doi.org/10.1016/j.neurol.2011.09.008.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Pichet Termsarasab & Thananan Thammongkolchai

  2. Department of Neurology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA

    Bashar Katirji

Authors
  1. Pichet Termsarasab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thananan Thammongkolchai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bashar Katirji
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Termsarasab, P., Thammongkolchai, T., Katirji, B. (2020). Treatment of Stiff-Person Spectrum Disorders. In: Stiff-Person Syndrome and Related Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-43059-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-43059-7_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-43058-0

  • Online ISBN: 978-3-030-43059-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation